LETTER TO THE EDITOR
SAFETY OF GLP-1RA THERAPY: SIDE EFFECTS AND THE NEED FOR MONITORING
 
More details
Hide details
1
Voivodeship Hospital in Kielce, Poland
 
2
4th Military Clinical Hospital, Wroclaw, Poland
 
3
University Hospital in Wroclaw, Poland
 
 
Submission date: 2024-07-31
 
 
Acceptance date: 2024-08-29
 
 
Publication date: 2024-09-20
 
 
 
KEYWORDS
TOPICS
REFERENCES (4)
1.
Bieganek P, Sadłowski B, Łukaszewicz S, Pawłowski P, Rybak J, Kordialik J, et al. Newly-emerging side effects of semaglutide and liraglutide usage associated with weight loss treatment. Health Prob Civil. Forthcoming 2024. https://doi.org/10.5114/hpc.20....
 
2.
Drucker DJ. Efficacy and safety of GLP-1 medicines for type 2 diabetes and obesity. Diabetes Care. 2024; dci240003. https://doi.org/10.2337/dci24-....
 
3.
Yang Z, Lv Y, Yu M, Mei M, Xiang L, Zhao S, et al. GLP-1 receptor agonist-associated tumor adverse events: a real-world study from 2004 to 2021 based on FAERS. Front. Pharmacol. 2022; 13:925377. https://doi.org/10.3389/fphar.....
 
4.
Silverii GA, Monami M, Gallo M, Ragni A , Prattichizzo F, Renzelli V, et al. Glucagon-like peptide-1 receptor agonists and risk of thyroid cancer: a systematic review and meta-analysis of randomized controlled trials. Diabetes Obes Metab. 2024; 26(3): 891-900. https://doi.org/10.1111/dom.15....
 
eISSN:2354-0265
ISSN:2353-6942
Journals System - logo
Scroll to top